ABSTRACT
The EPILOG trial showed that the platelet glycoprotein llb/llla inhibitor abciximab, together w i t h heparin in a low, w e i g h t -adjusted dose, markedly reduced the risk of acute ischemic complications during percutaneous coronary revascularization, w i t h o u t increasing the risk of hemorrhage.
- Copyright © 1998 The Cleveland Clinic Foundation. All Rights Reserved.
